控股股东 - NEXTEYE
NEXTEYE (137940. KR), founded in 1998 and listed in 2011, is mainly engaged in semiconductor visual inspection, health care products and cosmetics, and financial investment. As of December 31, 2022, NEXTEYE has 38 holding and participating companies worldwide. With the process of globalization, NEXTEYE's business has achieved explosive development and received high attention from the capital market. The highest daily turnover in 2021 will exceed 250 million dollars.
主营业务
The Global Eyesight, high-tech automatic image processing technology replace human eyes.
完善的国际大健康生态体系
全球最大规模美妆渠道拥有者-NEXTEYE
覆盖中国、韩国、东南亚、日本、美国销售渠道 拥有 4万 家终端门店，2亿 精选会员
Investment Holding Company
Korea's top five cosmetics
production and R&D institutions,
founder of BB cream.
The most authoritative nail company
in Korea, with a market share as high
as 70%, Leading the fashion trend of
Korean nail art.
A Korean hyaluronic acid
manufacturer, the only institution
that has been approved for the
second generation of hyaluronic acid
injections.
金融投资
NEXTEYE 先后投资或控股7家上市公司，投资或管理超过10支基金，总基金规模超过10亿美元。
其中与中信信托合作成立的“中信美尚大健康产业基金”，基金规模60亿人民币
经典案例
NEXTEYE分拆控股子公司赢多美丽（302430.KR）IPO上市。 2016年，赢多美丽（302430.KR）主营电动汽车锂电池检测， 作为一家仅有4名员工的研发企业没有业务收入， 2017年通过NEXTEYE获得中国大型企业比亚迪的过亿订单开始，迅速扩展市场，获得三星，LG,SK等大型锂电池企业订单， 是全球第一的X-Ray二次电池检测设备企业，仅用三年时间完成了业务从无到有，并IPO上市，企业估值从200万人民币到24亿人民币，提升高达1200倍的商业奇迹。
赢多美立挂牌前发行价（原始股） 参与机构902家，认购比例为765：1； 2020年NEXTEYE部分退出时，获得 440倍 投资回报。
